20
Participants
Start Date
January 31, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2028
Disitamab Vedotin combined with Toripalimab
Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
Zhejiang Tumor Hospital
OTHER
Fujian Provincial Hospital
OTHER
Zhangzhou Affiliated Hospital of Fujian Medical University
OTHER
Quanzhou First Hospital
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Fujian Medical University Union Hospital
OTHER